So, these are all issues that are being dealt with and parallel. I believe a lot of what we’ve been held up by is because of what happened with Roe V. Wade. That took a lot of the mind space down DC of how to handle that. What can the federal government do? So, we think we’re out of that. So, we think that, we’re rising to the top, reproductive health, and the contraceptive sectors coming up, and then that’s evidenced by the Biden executive order.
Naz Rahman: Thanks for that. And to dig a little deep on, Twirla’s performance to-date on this quarter, I know you talked quite a bit about the script growth, but could you provide some commentary on prescriber growth from Twirla? Like, how much are prescribers increasing? And how much of the growth do you think is due to just script yield versus prescribers at this point.
Alfred Altomari: I’ll let Amy handle it. I’ll collect it out.
Amy Welsh: Yes. It’s a great question to us because we recently were looking at that. So, we were coming here at the end of the year, and what we’re starting to see is, or we’re now understanding better. Most of our growth is coming from the new prescribers. And what that means is new patients. We’re seeing about 50%, 51% of our total scripts, week-over-week, month-over-month are coming from naive, our new patients. From a retail perspective, as a quarter, I know we already went through the data on the slides of Al, but we see a little over a 100 new prescribers each week. Some weeks, we see more, which is good, but that’s pretty much an average. So, let me know if I’ve got — or if you need any additional call on what I’ve already said, Naz.
Naz Rahman: Yes. Those prescribers, the new prescribers, do you find them consistently writing new scripts?
Amy Welsh: We see them coming in as new? Yes. They’re finding a patient that they think is a Twirla patient rather than switching from, a patch to a pill. That’s how they’re getting their first, confidence with Twirla. And then we see them after that, they’ll add more new, and then we see them starting to give us patch and pill. But to me that’s good. That’s good because, like, the patients that are coming in on their annual visits may or may not be talking about wanting to switch. So, what these physicians are doing is finding patients that want to get a new contraception, their thinking control is perfect for them. So, yes, these are 100 new prescribers or so a week are starting off typically putting Twirla on with a naive, female patient.
Naz Rahman: Got it. Thank you. And my last question, regarding this quarter, it seems like the growth in the retail channel and factory sales were — the quarter-over-quarter growth there was slower than it was in 2Q. Do you have any idea or comments around why that is, or is that just kind of an effect in Nurx?
Alfred Altomari: No. We don’t. No. This is going to be a little complicated, so bear with me. I mean, Amy and I were talking this morning and a lot of times they tell them prescribing doctors don’t get reported in this Symphony. So, we know we have a little bit more growth than you’re seeing, but for right now, we just want to kind of leave that off to the side until it’s got a bigger head of steam. So, we know we’re doing our puts, better than Symphony’s reporting in the retail channel. But that said, we shouldn’t be I’m not, at all disappointed with putting off double-digit growth. And, look, if you look around the sector, and just look around women’s health or specialty pharm. I mean, consistently putting up double-digit growth on a quarter-by-quarter basis is no small feet, but particularly as our business gets bigger, Naz, look, it’s harder to beat a bigger number, right?
